Actively Recruiting
A Post Marketing Surveillance on Piqray in Korea
Led by Novartis Pharmaceuticals · Updated on 2025-07-09
900
Participants Needed
17
Research Sites
254 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, multicenter, open-label, non-comparative, non-interventional, observational study to assess te safety and effectiveness of Piqray in the real-world setting
CONDITIONS
Official Title
A Post Marketing Surveillance on Piqray in Korea
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Postmenopausal women and men with confirmed hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer
- Patients who have progressed after prior endocrine therapy
- Patients starting Piqray treatment for the first time according to local label
- Patients willing to provide written informed consent
You will not qualify if you...
- Patients with contraindications to Piqray, including severe hypersensitivity to Piqray or its components
- Female patients who are pregnant or breastfeeding
- Patients who are sexually active but unwilling to follow contraceptive precautions while taking Piqray
- Patients receiving or planning to receive any investigational medicine during the study period
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 17 locations
1
Novartis Investigative Site
Cheonan Si, Chungcheongnam-do, South Korea, 31116
Actively Recruiting
2
Novartis Investigative Site
Daegu, Dalseo gu, South Korea, 42602
Actively Recruiting
3
Novartis Investigative Site
Deogyang Gu Goyang Si, Gyeonggi-do, South Korea, 10475
Actively Recruiting
4
Novartis Investigative Site
Suwon, Gyeonggi-do, South Korea, 16499
Actively Recruiting
5
Novartis Investigative Site
Gyeonggi-do, Korea, South Korea, 11765
Actively Recruiting
6
Novartis Investigative Site
Busan, South Korea, 48108
Actively Recruiting
7
Novartis Investigative Site
Busan, South Korea, 602-030
Actively Recruiting
8
Novartis Investigative Site
Daegu, South Korea, 705 718
Actively Recruiting
9
Novartis Investigative Site
Daejeon, South Korea, 302-241
Actively Recruiting
10
Novartis Investigative Site
Jeollanam, South Korea, 519763
Actively Recruiting
11
Novartis Investigative Site
Seoul, South Korea, 02841
Actively Recruiting
12
Novartis Investigative Site
Seoul, South Korea, 03722
Actively Recruiting
13
Novartis Investigative Site
Seoul, South Korea, 04763
Actively Recruiting
14
Novartis Investigative Site
Seoul, South Korea, 05505
Actively Recruiting
15
Novartis Investigative Site
Seoul, South Korea, 06273
Actively Recruiting
16
Novartis Investigative Site
Seoul, South Korea, 06351
Completed
17
Novartis Investigative Site
Seoul, South Korea, 158-710
Actively Recruiting
Research Team
N
Novartis Pharmaceuticals
CONTACT
N
Novartis Pharmaceuticals
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here